Truvestments Capital’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-260
| Closed | -$33.3K | – | 1062 |
|
|
2025
Q2 | $33.3K | Buy |
260
+162
| +165% | +$16.8K | 0.01% | 466 |
|
|
2025
Q1 | $8.67K | Hold |
98
| – | – | ﹤0.01% | 679 |
|
|
2024
Q4 | $8.55K | Hold |
98
| – | – | ﹤0.01% | 628 |
|
|
2024
Q3 | $9.06K | Buy |
+98
| New | +$9.73K | ﹤0.01% | 597 |
|
|
2024
Q2 | – | Sell |
-35
| Closed | -$3.32K | – | 288 |
|
|
2024
Q1 | $3.32K | Hold |
35
| – | – | ﹤0.01% | 582 |
|
|
2023
Q4 | $3.23K | Hold |
35
| – | – | ﹤0.01% | 644 |
|
|
2023
Q3 | $1.76K | Hold |
35
| – | – | ﹤0.01% | 599 |
|
|
2023
Q2 | $2.21K | Hold |
35
| – | – | ﹤0.01% | 597 |
|
|
2023
Q1 | $1.57K | Sell |
35
-16
| -31% | -$721 | ﹤0.01% | 591 |
|
|
2022
Q4 | $2.23K | Hold |
51
| – | – | ﹤0.01% | 706 |
|
|
2022
Q3 | $3K | Hold |
51
| – | – | ﹤0.01% | 506 |
|
|
2022
Q2 | $3K | Buy |
+51
| New | +$2.99K | ﹤0.01% | 522 |
|
|
2022
Q1 | – | Sell |
-51
| Closed | -$5K | – | 234 |
|
|
2021
Q4 | $5K | Sell |
51
-21
| -29% | -$2.2K | ﹤0.01% | 474 |
|
|
2021
Q3 | $7K | Hold |
72
| – | – | ﹤0.01% | 413 |
|
|
2021
Q2 | $6K | Hold |
72
| – | – | ﹤0.01% | 435 |
|
|
2021
Q1 | $7K | Buy |
72
+17
| +31% | +$1.7K | ﹤0.01% | 482 |
|
|
2020
Q4 | $6K | Buy |
+55
| New | +$5.8K | ﹤0.01% | 474 |
|
|
2020
Q3 | – | Sell |
-55
| Closed | -$4K | – | 352 |
|
|
2020
Q2 | $4K | Buy |
+55
| New | +$3.72K | ﹤0.01% | 469 |
|
|
2019
Q4 | – | Sell |
-96
| Closed | -$7K | – | 203 |
|
|
2019
Q3 | $7K | Sell |
96
-9
| -9% | -$778 | ﹤0.01% | 528 |
|
|
2019
Q2 | $10K | Hold |
105
| – | – | 0.01% | 529 |
|
|
2019
Q1 | $8K | Buy |
+105
| New | +$7.76K | 0.01% | 534 |
|
|
2018
Q3 | $9K | Buy |
+111
| New | +$7.71K | ﹤0.01% | 653 |
|
Other funds holding BPMC
IA
HNB
Truvestments Capital's BPMC Position: Q3 2025 in Review
Truvestments Capital sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 260 shares — an estimated $33.3K sold.
Truvestments Capital first reported a position in BPMC in Q3 2018 and held it in 22 quarters. The position peaked at $33.3K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Truvestments Capital reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Truvestments Capital sold 260 Blueprint Medicines shares in Q3 2025, an estimated $33.3K.
- Truvestments Capital first reported a position in Blueprint Medicines in Q3 2018 and held it in 22 quarters.
- Truvestments Capital's Blueprint Medicines position peaked at $33.3K in Q2 2025.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Truvestments Capital's 13F filing for Q3 2025, filed 14 Nov 2025.